Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results

WOODCLIFF LAKE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today filed with the U.S. Securities and Exchange Commission (SEC) its Form 10-Q for the third quarter of 2007. The filing of Par's Form 10-Q for this period had been delayed due to the work involved in restating its consolidated financial statements for certain prior periods, which were filed earlier this year. As a result of today's filing, the Company is now up-to-date on all of its reporting obligations with the SEC.

Third-Quarter and Nine-Month Results

For the third quarter ended September 29, 2007, Par reported total revenues of $212.7 million and net income of $1.3 million, or $0.04 per diluted share. This is compared with reported revenues of $174.0 million and net income of $4.4 million, or $0.13 per diluted share, for the same period in 2006. For the nine months ended September 29, 2007, Par reported total revenues of $614.5 million and net income of $45.6 million, or $1.30 per diluted share. This is compared with reported revenues of $541.5 million and net income $1.7 million, or $0.05 per diluted share, for 2006.

Third-quarter 2007 reported, or GAAP, results include $16.2 million of costs related to business development activities in support of the Company's branded division, Strativa, which are discussed in more detail below. Adjusting for this item, net income for the third quarter 2007 was $11.1 million, or $0.32 per diluted share. By comparison, third-quarter 2006 results included $7.1 million of severance costs and a $1.2 million net gain relating to the sale of certain product rights. Adjusting for these items, the Company posted net income of $8.0 million, or $0.23 per diluted share for the third-qu $1,269 $4,387 $45,581 $1,696

Earnings per share of common


Basic $0.04 $0.13 $1.31 $0.05

Diluted $0.04 $0.13 $1.30 $0.05

Weighted average number of

common shares outstanding:

Basic 34,738 34,468 34,677 34,401

Diluted 34,906 34,566 34,949 34,636

Reconciliation Between Reported (GAAP) and Adjusted Net Income

(In thousands, except per share data)


Three Months Ended

September 29, September 30,

2007 2006

Reported Net Income $1,269 $4,387

Branded License Fees and Premium Paid on Equity

Investment 16,150 -

Gain on Sale of Product Rights* - (1,150)

Severance Costs - 7,106

Estimated Tax on Adjustments (6,299) (2,323)

Adjusted Net Income (non-GAAP measure) $11,121 $8,020

Diluted Earnings Per Share:

Reported $0.04 $0.13

Adjusted (non-GAAP measure) $0.32 $0.23

Nine Months Ended

September 29, September 30,

2007 2006

Reported Net Income $45,581 $1,696

Gain on Sales of Product Rights* (20,000) (1,150)

Net Investment Loss 4,643 3,773

Branded License Fees and Premium Paid on Equity

Investments 19,150 -

Severance Costs 1,643 7,106

Net Settlements (Gain) Losses (578) 1,502

Write-off of Accounts Receivable Relating to

Invalid Customer Deductions - 9,965

Estimated Tax on Adjustments (1,895) (8,266)

Adjusted Net Income (non-GAAP measure) $48,544 $14,626

Diluted Earnings Per Share:

Reported $1.30 $0.05

Adjusted (non-GAAP measure) $1.39 $0.42

* 2006 amounts represent $3,054 gain on sale of product rights net of

$1,904 loss on the return of inventory from a customer relating to the

same agreement.

Estimated Operating Results for Full Year 2007


(in millions, except per share amounts)

Total Revenue $760 - $780

SG&A $130 - $133

R&D $75 - $80

Reported GAAP EPS (fully diluted) $1.45 - $1.50

Other supplemental information

Depreciation & amortization $24 - $26

Share-based compensation $18 - $20


(in millions, except per share amounts)

Reported GAAP EPS (fully diluted) $1.45 - $1.50

Severance $2

Branded Milestone Payments $19

High Yield Investment Loss $6

PAR 101 $(24)

Estimated Tax on Adjustments $(1)

Total Non-GAAP Items $2

EPS Impact (fully diluted) $0.05

EPS (fully diluted)

adjusted for non-GAAP items $1.50 - $1.55

arter of 2006.

In addition, Par's reported, or GAAP, results for the first nine months of 2007, included a $20.0 million gain on the sale to Optimer Pharmaceutical, Inc. of marketing rights to the investigational drug Difimicin, a $1.4 million investment gain on the sale of shares of Optimer common stock, and net settlement gains of $0.6 million, tempered by a $6.0 million loss on investment, a $3.0 million license fee paid to Immtech Pharmaceuticals for commercialization rights to the developmental drug pafuramidine and $1.6 million of severance costs. Adjusting for these items, net income for the nine months ended September 29, 2007 was $48.5 million, or $1.39 per diluted share. By comparison, reported GAAP results for the nine months ended September 30, 2006 also included a write-off of approximately $10.0 million of accounts receivable relating to invalid customer deductions, the collection of which the Company determined that it would no longer pursue, severance costs, and net investment and arbitration settlement losses. Adjusting for these items, net income for the first nine months of 2006 was $14.6 million, or $0.42 per diluted share (see reconciliation between reported (GAAP) and adjusted net income at the end of this press release).

Third-Quarter Review

For the third quarter ended September 29, 2007, total revenues increased 22.2 percent compared with the same period in 2006 due primarily to new product introductions. The third quarter launch of three additional strengths of metoprolol succinate ER (50mg, 100mg, and 200mg), coupled with the fourth quarter 2006 launch of the 25mg strength, drove $71.7 million of sales and corresponding year-over-year gains. Par markets metoprolol in the U.S. through supply and distribution agreements with AstraZeneca Plc. In addition, the first quarter 2007 introductions of propranolol HCl extended release (ER) capsules and ranitidine HCl syrup benefited the third-quarter by $12.1 million and $4.4 million, respectively. Partially offsetting the increases were lower sales of certain existing products due to competitive pressures, including fluticasone, various amoxicillin products, quinapril, megestrol oral suspension, and doxycycline. Revenues of branded products for the third quarter of 2007 of $24.6 million, an increase of 72.5 percent over the prior year period, were driven by increased sales of Megace(R) ES (megestrol acetate) oral suspension, and fees related to the co-promotion of AndroGel(R).

Par's third-quarter gross margin was 31.2 percent of sales, compared to 31.6 percent in 2006. The Company's gross margin reflects the impact of increased metoprolol succinate ER sales, which have significantly lower gross margin percentages than many of the other products sold by the Company. This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on other lower margin products, including fluticasone.

Research and development (R&D) expenses increased 161.0 percent for the third quarter 2007 compared with the third quarter 2006. The increase was due primarily to costs associated with the in-license of two Phase III products in support of the Company's branded division, Strativa. In July, the Company paid $15 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense in the quarter. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd. (IPC), a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.5 million, representing the premium paid, was charged to R&D in the third quarter.

Third-quarter selling, general and administrative (SG&A) expense decreased 15.3 percent to $33.9 million. The decrease in 2007 SG&A expense was primarily due to the non-recurrence of severance costs incurred in 2006 for executives of $7.1 million, partially offset by increased costs associated with the expansion of finance and accounting functions and increased professional costs related to the Company's restatement of prior periods.

2007 Financial Outlook

Par has adjusted its previously announced guidance for full-year 2007 earnings per diluted share of $1.45-$1.50 from $1.35-$1.50. Total net revenue is expected to be between $760-$780 million. SG&A is expected to be $130-$133 million, including approximately $2 million in severance costs. Research and development cost is projected to be in the range of $75-$80 million, including approximately $19 million in branded milestone payments. Total projected expenses for the full-year include approximately $18-20 million of share-based compensation and $24-$26 million of depreciation and amortization expenses. Adjusting for non-GAAP items highlighted on the summary of estimated operating results for full year 2007 at the end of this press release, full year earnings per diluted share is projected to be $1.50-$1.55.

Stock Repurchase Program

Since October 1, 2007, Par has repurchased 1,643,094 shares of its common stock at a total cost of $31.5 million. On September 28, 2007, Par announced that its Board of Directors had authorized the repurchase of up to $75 million of the Company's common stock.

Conference Call

Par has scheduled a conference call for Thursday, December 20, 2007 at 9:00 am EST to discuss results for the third quarter of 2007. Par invites investors and the general public to listen to a webcast of the conference call. Access to the live webcast can be made via the Company's website at and will be available for at least 30 days. The dial-in number is 800-265-0241 for domestic callers and 617-847-8704 for international callers. The access number is 56870475. A replay of the conference call will be available commencing approximately one hour after the call. The replay dial-in number is 888-286-8010 for domestic callers and 617-801-6888 for international callers. The access number is 95070288.

For a copy of Par's Form 10-Qs for the quarterly period ended September 29, 2007, visit Investors/SEC Filings on the Par web site at

Non-GAAP Measures

Par prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). In an effort to provide investors with additional information regarding the Company's results and to provide a meaningful year-over-year comparison of the Company's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission. The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in the attached. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating the Company's underlying business performance. Management uses the non-GAAP financial measures to evaluate the Company's financial performance against internal budgets and targets. In addition, management internally reviews the results of the Company excluding the impact of certain items, as it believes that these non- GAAP financial measures are useful for evaluating the Company's core operating results and facilitating comparison across reporting periods. Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures. The Company's non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward- looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.



(In Thousands, Except Share Data)


September 29, December 31,

ASSETS 2007 2006

Current assets:

Cash and cash equivalents $114,161 $120,991

Available for sale debt and marketable

equity securities 173,544 92,120

Accounts receivable, net 108,182 99,043

Inventories 81,049 106,322

Prepaid expenses and other current assets 13,623 15,833

Deferred income tax assets 72,105 72,105

Income taxes receivable 6,605 12,422

Total current assets 569,269 518,836

Property, plant and equipment, at cost

less accumulated depreciation and

amortization 81,902 89,155

Available for sale debt and marketable

equity securities 7,233 7,652

Investment in joint venture 5,774 5,292

Other investments 2,500 16,588

Intangible assets, net 38,719 47,880

Goodwill 63,729 63,729

Deferred charges and other assets 2,879 16,000

Non-current deferred income tax assets, net 57,485 49,545

Total assets $829,490 $814,677


Current liabilities:

Short-term and current portion of

long-term debt $200,019 $204,469

Accounts payable 30,546 48,297

Payables due to distribution agreement

partners 65,586 89,585

Accrued salaries and employee benefits 13,413 15,510

Accrued expenses and other current

liabilities 25,168 18,833

Income taxes payable 58 16,974

Total current liabilities 334,790 393,668

Long-term debt, less current portion - -

Other long-term liabilities 13,718 -

Commitments and contingencies - -

Stockholders' equity:

Preferred Stock, par value $0.0001 per

share, authorized 6,000,000 shares;

none issued and outstanding - -

Common Stock, par value $0.01 per share,

authorized 90,000,000 shares, issued

36,421,650 and 35,901,276 shares 364 359

Additional paid-in-capital 267,994 254,013

Retained earnings 245,837 200,256

Accumulated other comprehensive income

(loss) 1,351 (431)

Treasury stock, at cost 942,716 and

889,245 shares (34,564) (33,188)

Total stockholders' equity 480,982 421,009

Total liabilities and stockholders' equity $829,490 $814,677



(In Thousands, Except Per Share Data)


Three months ended Nine months ended

September September September September

29, 30, 29, 30,

2007 2006 2007 2006


Net product sales $206,923 $168,951 $589,526 $528,571

Other product related

revenues 5,753 5,028 25,000 12,964

Total revenues 212,676 173,979 614,526 541,535

Cost of goods sold 146,248 118,919 403,854 382,540

Gross margin 66,428 55,060 210,672 158,995

Operating expenses:

Research and development 32,815 12,574 61,131 43,983

Selling, general and

administrative 33,910 40,053 100,466 111,337

Settlements, net (367) - (945) 1,250

Total operating expenses 66,358 52,627 160,652 156,570

Gain on sale of product rights - 3,054 20,000 3,054

Operating income 70 5,487 70,020 5,479

Other (expense) income, net - (38) (49) 66

Equity in loss of joint

venture (107) (18) (335) (497)

Loss on marketable

securities, net - - (4,643) (3,773)

Interest income 3,680 2,098 10,265 6,055

Interest expense (1,691) (1,681) (5,136) (5,069)

Income before provision for

income taxes 1,952 5,848 70,122 2,261

Provision for income taxes 683 1,461 24,541 565

Net income

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their record books ... their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA ... rebuild lives and it’s an honor to have served all of these women.” , ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and ... an application server to improve system efficiency and reliability. , The new Q-Suite 6 ... these standards, the system avoids locking itself into a specific piece of software for ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... 25, 2015  Henry Schein, Inc., the world,s largest ... dental, medical and animal health practitioners, will unveil at ... Henry Schein ConnectDental® Pavilion , which brings together for ... solutions designed to help any practice or laboratory enter ... for a schedule of experts appearing at the Pavilion. ...
Breaking Medicine Technology: